When compared to 2D conventional cell culture systems, experimental data obtained with 3D cell culture models have been shown in many instances to be more biologically relevant, closer to clinical conditions (eg. predictive assays/preclinical therapeutic testing).

In this context, tebu-bio laboratories have developed a spheroid platform with a selection of downstream analysis applications such as live cell imaging, microfluidic and physioxia culture conditions or downstream multiplex biomarker quantification, among others.

If you need more physiologically relevant models for your study, but you don’t have access to the technologies or haven’t the time to spend on setting up spheroid cultures in your own laboratories, read on to see what tebu-bio laboratories can generate for you in terms of data.

This year again, we were pleased to attend the Annual meeting of the AACR (American Association for Cancer Research), which took place in Chicago, USA earlier this month.

Dora Sabino PhD of tebu-bio at the AACR2018 Poster Session

Dora Sabino PhD of tebu-bio at the AACR2018 Poster Session

Dora Sabino PhD of tebu-bio at the AACR2018 Poster Session

Dora Sabino Ph.D. (3D Cell Culture Project Manager, tebu-bio) presented a poster covering a physiologically relevant study on 3D colon cancer models in microfluidic chips:

“Time-lapse analysis of drug response and invasive capacity using patient-derived and CRC microfluidic 3D cancer models under oxygen controlled conditions”

Download your copy of the poster here and learn more about tebu-bio’s laboratory outsourcing solutions.

Tumour modelling facilitates the study of tumour growth in the tumour microenvironment (TME). Therapies that affect the tumour microenvironment are critical for advancing the fight against cancer as emerging therapies target the network of signaling pathways essential for tumour growth, Epithelial Mesenchymal Transition and metastasis (ex. Wnt/ß-Catenin pathway). Patient derived tumour models, including melanoma cell lines, are invaluable tools to study normal and malignant cells, tumour formation and drug resistance.

Rockland Immunochemicals Inc. has partnered with the Wistar Research Institute, to produce and validate a diverse panel of low passage melanoma cell lines from freshly excised metastases. More than 100 melanoma cell lines are grouped for BRAF, N-RAS, KIT, PTEN and CDK4 mutations.  These pre-clinical tumour cell lines models can be used to identify the critical target genes and pathways enacted by genomic alterations and lead to more accurately prediction of the effectiveness of novel cancer therapeutics and facilitate cancer research.